REGN - Spark Newswire

2 minute read

Earnings

Regeneron Pharmaceuticals Earnings Perspective: Return On Invested Capital

Today, 11:57 PM

Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q3 earnings of $1.85 billion, an increase from Q2 of 44.81%. Sales dropped to $3.45 billion, a 32.81% decrease between quarters.

REGN

32 minute read

Earnings Scheduled For November 4, 2021

By Benzinga Insights

Today, 11:57 PM

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 11:57 PM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT

4 minute read

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs

By Shanthi Rexaline

Today, 11:57 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

1 minute read

Analyst Ratings

Where Regeneron Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 11:57 PM

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

REGN

1 minute read

SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $798

By Benzinga Newsdesk

Today, 11:57 PM

SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $785 to $798.

REGN

5 minute read

Regeneron Early Monday Morning Announced Phase 3 Results From Trial Assessing Investigational Use Of Co.’s Dupixent In Patients 12+ With Eosinophilic Esophagitis

By Benzinga Newsdesk

Today, 11:57 PM

Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial

REGN

4 minute read

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More

By Shanthi Rexaline

Today, 11:57 PM

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

ABBV